Trials / Completed
CompletedNCT00456560
AV650 Drug-Drug Interaction Study
A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Avigen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects that paroxetine and fluvoxamine have on the way the body distributes, breakdowns and eliminates AV650. In addition, information about any side effects that may occur will also be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AV650 | |
| DRUG | Fluvoxamine | |
| DRUG | Paroxetine |
Timeline
- Start date
- 2007-04-01
- Completion
- 2007-05-01
- First posted
- 2007-04-05
- Last updated
- 2007-09-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00456560. Inclusion in this directory is not an endorsement.